

Health Advisory

Treating Patients with Coronavirus Disease 2019 (COVID-19) with Monoclonal Antibodies May 3, 2021

In ambulatory patients who test positive for SARS-CoV-2 and are at high risk for severe disease, treatment with monoclonal antibodies (casirivimab/imdevimab or bamlanivimab/etesevimab) has demonstrated a reduction in mortality and hospitalization.

Treatment should be started as soon as possible after the patient receives a positive result on a SARS-CoV-2 molecular or antigen test and must begin within 10 days of symptom onset. Treatment is performed by IV infusion.

Patients who have been vaccinated and subsequently tested positive for SARS-CoV-2 are eligible for monoclonal antibodies.

SUMMARY POINTS

- Ambulatory patients with mild to moderate COVID-19 who are at risk for progression to severe disease may benefit from treatment with monoclonal antibodies.
- Several area health systems are offering treatment with monoclonal antibodies.

Patient Eligibility

Monoclonal antibodies directed against SARS-CoV-2 may be used in adults and children ≥ 12 years and weighing ≥ 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Patients are considered at high risk if they meet any one of the following criteria:

- Body mass index (BMI) ≥ 35
- Chronic kidney disease
- Diabetes mellitus
- Immunocompromising condition
- Currently receiving immunosuppressive treatment
- Aged ≥ 65 years
- Aged ≥ 55 years and have:
 - Cardiovascular disease; or
 - Hypertension; or
 - Chronic obstructive pulmonary disease/other chronic respiratory disease.
- Aged 12 to 17 years and have:
 - BMI ≥ 85 th percentile for their age and gender based on the [Centers for Disease Control and Prevention growth charts](#); or
 - Sickle cell disease; or
 - Congenital or acquired heart disease; or
 - Neurodevelopmental disorders (e.g. cerebral palsy); or
 - A medically related technological dependence that is not related to COVID-19 (e.g. tracheostomy, gastrostomy, positive pressure ventilation); or
 - Asthma or a reactive airway or other chronic respiratory disease that requires daily medication for control

Individual area health systems may have further inclusion and exclusion criteria.

How to Refer a Patient

Health System	Internal Referrals	External Referrals	Address
Jefferson Health	EPIC Referral	Call 215-955-7785.	Jefferson Center City Campus
Chestnut Hill Hospital	EPIC Referral	Administered through the ER	8835 Germantown Ave.
Penn Medicine	PennChart Consult	REDCap Referral from: <ul style="list-style-type: none"> • Health Centers 3/4 • Puentes de Salud • Philadelphia Fight • Oak Street Clinics • Ninth Street Internal Medicine • Family Practice and Counseling Network • Sayre Health • Spectrum Health 	Hospital of the University of Pennsylvania
Temple University Hospital	EPIC Referral	Email TFPCOV@tuhs.temple.edu	Temple University Hospital (Broad and Tioga, 5th Floor Outpatient Building)
Einstein Health	EMR Referral		5501 Old York Road